Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease (ELAB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00579046|
Recruitment Status : Withdrawn (no patient recruiting)
First Posted : December 21, 2007
Last Update Posted : October 30, 2013
|Condition or disease||Intervention/treatment||Phase|
|Anemia Chronic Obstructive Pulmonary Disease||Drug: Darbepoetin alfa||Phase 3|
The development of anemia in patients with chronic obstructive pulmonary disease (COPD) is now taken as a predictor of increased morbidity and mortality. Preliminary data from patients investigated in our department indicate a negative correlation between anemia severity and 6-minute walking distance. Our working hypothesis is that hemoglobin level correction by erythropoietin therapy will improve the effort capacity of patients with COPD and anemia. Our objective is to conduct a pilot study of the efficacy of darbepoetin alfa.
The study will include about 15 patients with COPD recruited at three pulmonology centers based on two selection criteria: COPD stage II or III or IV according to GOLD criteria and hemoglobin level less than 12 g/dL. Effort capacity will be evaluated chiefly by performing a 6-minute walking test and by measuring VO2 at maximum exertion on a bicycle ergometer with increasing loads. Darbepoetin alfa will be given for 2 months. If the hemoglobin increase is less than 1 g/dL after 1 month, the dosage will be increased by 25%.
Effort parameters will be measured at baseline and after 1 and 2 months of treatment. Among secondary objectives, we will evaluate functional ergospirometric parameters and laboratory tests for inflammation. Total study duration will not exceed 18 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Erythropoietin Treatment of Anemia Complicating Chronic Obstructive Pulmonary Disease: Functional Impact During Exertion|
|Study Start Date :||November 2008|
|Actual Primary Completion Date :||October 2009|
|Estimated Study Completion Date :||October 2009|
Drug: Darbepoetin alfa
Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).
Frequency: every week for 2 months: 8 injections
- Measure: 6-minute walk distance [ Time Frame: before treatment; at one month and two months of treatment ]
- VO2 max [ Time Frame: before treatment; at one month and two months ]
- MRC Dyspnea score [ Time Frame: before treatment; at one month and two months ]
- St. George quality of life score [ Time Frame: before treatment and at two months of treatment ]
- Inflammation biological parameters [ Time Frame: before treatment and at two months of treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00579046
|CHU Henri Mondor|
|Creteil, France, 94 000|
|Principal Investigator:||Laurent Savale, MD||Assistance Publique - Hôpitaux de Paris|